The Safety and Effectiveness of a Type of Interleukin-2 Plus Zidovudine Plus Thymosin in HIV-Positive Patients With and Without Symptoms of Infection

Inclusion Criteria Concurrent Medication: Allowed: * Prophylactic pentamidine for Pneumocystis carinii. Patients must have: * HIV seropositivity. * CD4 count \> 50 and \< 200 cells/mm3. * No active opportunistic infections. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: * Concurrent neoplasms other than basal cell carcinoma of the skin, in situ carcinoma of the cervix, or Kaposi's sarcoma. * Significant cardiac disease or CNS lesions or other neurologic abnormalities. * Score of \> 0.5 on ACTG AIDS Dementia Complex staging. * Major organ allograft. * Intolerance to AZT at 500 mg/day. Concurrent Medication: Excluded: * Antihypertensive medication other than diuretics. * Chemotherapy, hormonal therapy, or other immunotherapy. * Other investigational drugs, agents, or devices. * Beta-blockers. * Non-topical steroids. Concurrent Treatment: Excluded: * Radiation therapy. Prior Medication: Excluded: * Known anti-HIV medication (other than AZT) or known immunomodulators (e.g., systemic steroids, interferons, interleukins) or other chemotherapy within 30 days prior to study entry. Prior Treatment: Excluded: * Transfusion within 4 weeks prior to study entry. * Radiation within 30 days prior to study entry. Active substance abuse.